Marshall Wace
MYGN icon

Marshall Wace’s Myriad Genetics MYGN Stock Holding History

Marshall Wace’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.97M Buy
1,103,758
+1,081,456
+4,849% +$5.63M ﹤0.01% 1310
2025
Q4 		$137K Sell
22,302
-25,395
-53% -$184K ﹤0.01% 2667
2025
Q3 		$345K Sell
47,697
-20,329
-30% -$121K ﹤0.01% 2375
2025
Q2 		$361K Buy
+68,026
New +$402K ﹤0.01% 2260
2024
Q4 		– Sell
-114,306
Closed -$3.13M – 2859
2024
Q3 		$3.13M Buy
+114,306
New +$3.09M ﹤0.01% 1188
2024
Q2 		– Sell
-33,557
Closed -$715K – 2808
2024
Q1 		$715K Buy
+33,557
New +$721K ﹤0.01% 1788
2023
Q1 		– Sell
-147,004
Closed -$2.13M – 2956
2022
Q4 		$2.13M Buy
+147,004
New +$2.74M ﹤0.01% 1695
2022
Q2 		– Sell
-91,025
Closed -$2.29M – 3701
2022
Q1 		$2.29M Buy
+91,025
New +$2.33M ﹤0.01% 1971
2020
Q4 		– Sell
-78,441
Closed -$1.02M – 2079
2020
Q3 		$1.02M Sell
78,441
-149,211
-66% -$1.89M 0.01% 1026
2020
Q2 		$2.58M Buy
+227,652
New +$3.23M 0.02% 697
2019
Q3 		– Sell
-155,916
Closed -$4.33M – 1843
2019
Q2 		$4.33M Buy
+155,916
New +$4.4M 0.04% 532
2019
Q1 		– Sell
-336,435
Closed -$9.78M – 1946
2018
Q4 		$9.78M Buy
+336,435
New +$12.1M 0.1% 247
2017
Q1 		– Sell
-10,675
Closed -$178K – 594
2016
Q4 		$178K Sell
10,675
-108,255
-91% -$1.96M ﹤0.01% 930
2016
Q3 		$2.45M Sell
118,930
-202,731
-63% -$5.14M 0.02% 555
2016
Q2 		$9.84M Buy
+321,661
New +$11.2M 0.08% 254
2015
Q2 		– Sell
-458,080
Closed -$16.2M – 993
2015
Q1 		$16.2M Buy
+458,080
New +$16.4M 0.21% 131

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's MYGN Position: Q1 2026 in Review

Marshall Wace increased its Myriad Genetics (MYGN) stake by 4,849% in Q1 2026, buying an estimated $5.63M and bringing the position to 1,103,758 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

Marshall Wace first reported a position in MYGN in Q1 2015 and has held it in 16 quarters since. The position peaked at $16.2M in Q1 2015. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Marshall Wace held 1,103,758 shares of Myriad Genetics worth $4.97M as of Q1 2026.
  • Marshall Wace bought 1,081,456 Myriad Genetics shares in Q1 2026, an estimated $5.63M.
  • Myriad Genetics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1310 holding.
  • Marshall Wace first reported a position in Myriad Genetics in Q1 2015 and has held it in 16 quarters since.
  • Marshall Wace's Myriad Genetics position peaked at $16.2M in Q1 2015.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.